Jover Placid 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Teva (TEVA) CHRO Jover Placid Sells 14,150 Shares
What Happened
Jover Placid, Executive Vice President and Chief Human Resources Officer of Teva Pharmaceutical Industries (TEVA), had 14,150 restricted share units vest on March 5, 2026. Those RSUs were converted to ordinary shares and immediately sold in the open market the same day, generating approximately $448,108 in proceeds (weighted average sale price $31.67).
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (filed within the two-business-day deadline).
- Sale: 14,150 shares sold in multiple trades at a weighted average price of $31.67 (range $31.26–$32.34). Proceeds ≈ $448,108.
- Derivative/vesting: 14,150 RSUs vested and were converted to shares (reported as exercise/conversion of derivative). The filing indicates the shares vested were sold, including shares sold to cover tax withholding.
- Plan/authorization: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 10, 2025.
- Shares owned after transaction: Not specified in this filing.
- Other notes: Ordinary shares may be represented by American Depositary Shares (ADS); RSU grant and vesting schedule referenced in the filing.
Context
This was a routine sale following RSU vesting and conversion, not a discretionary open-market purchase. The RSUs were granted previously (series with equal tranches vesting annually through 2029), and the filing shows the vested shares were converted and sold immediately—effectively a cashless settlement to realize value and cover tax obligations. The use of a 10b5-1 plan indicates the sales were pre-planned rather than ad hoc.
Insider Transaction Report
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+14,150→ 20,924 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-05$31.67/sh−14,150$448,108→ 6,774 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-05−14,150→ 42,453 total→ Ordinary Shares (14,150 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- [F4]Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029.